Genmab's Impressive Sales Performance for DARZALEX in 2024
Genmab A/S, a leading biotechnology company, has reported remarkable net sales figures for its product DARZALEX® (daratumumab) in 2024, reaching an astounding USD 11,670 million. This significant achievement underscores the company's ongoing commitment to developing innovative treatments for patients facing serious health challenges.
Overview of DARZALEX's Global Sales
The overall net sales of DARZALEX, including its subcutaneous formulation known as DARZALEX FASPRO, highlight Genmab's successful collaboration with Johnson & Johnson (J&J). In the U.S. market alone, the net sales amounted to USD 6,588 million, while the rest of the world contributed USD 5,082 million. This distribution showcases the product's robust performance across various regions, reflecting growing acceptance and trust in this life-changing treatment.
Partnership with Johnson & Johnson
Genmab's partnership with J&J plays a crucial role in the commercialization of DARZALEX. Under an exclusive worldwide license, Genmab receives royalties on sales generated both from the intravenous and the subcutaneous forms of daratumumab. Collaborations like these enable Genmab to expand its reach and impact on patient lives globally.
About Genmab's Commitment to Innovation
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab is dedicated to improving patient outcomes through antibody therapeutics. The company thrives on a culture of innovation, having developed next-generation antibody technology platforms over its 25 years of operation. Genmab's pipeline includes revolutionary treatments such as bispecific T-cell engagers, antibody-drug conjugates, and immune checkpoint modulators, demonstrating its commitment to transformative medicine.
Vision for the Future
Genmab's ambitious vision aims for transformative innovations in the biotech field by 2030. They are committed to providing groundbreaking antibody-based therapies that genuinely enhance the quality of life for individuals battling cancer and other serious diseases. This forward-thinking approach, characterized by passion and collaboration, positions Genmab as a pivotal player in the biotechnology landscape.
Company Growth and Broader Impact
As an international player with a significant presence in North America, Europe, and Asia Pacific, Genmab's ability to grow its market share is vital to its mission. Their products are not only advanced therapeutics but also a promise of hope to patients worldwide. Continuous investment in research and development is at the core of their strategy, which acknowledges the challenges within the competitive biotech sector.
Contact Information and Further Engagement
For interested parties seeking more information regarding Genmab's innovations or investment opportunities, the company encourages direct communication. Marisol Peron, Senior Vice President of Global Communications & Corporate Affairs, is the primary contact for inquiries, available at +1 609 524 0065 or via email at mmp@genmab.com. Meanwhile, Andrew Carlsen, Vice President of Investor Relations, can be reached at +45 3377 9558 or acn@genmab.com.
Frequently Asked Questions
What is DARZALEX?
DARZALEX is a monoclonal antibody therapy used for treating multiple myeloma, demonstrating significant efficacy in clinical settings.
How has Genmab performed in recent years?
Genmab has demonstrated impressive growth, with net sales of DARZALEX reaching USD 11,670 million in 2024.
What role does Johnson & Johnson play in Genmab's operations?
Johnson & Johnson partners with Genmab to commercialize DARZALEX, allowing Genmab to receive royalties on worldwide sales.
What is Genmab's vision for the future?
Genmab aims to transform patient care with innovative antibody medicines by 2030.
How can I find more information about Genmab's products?
For further details, you can visit Genmab's website or contact their corporate communications team directly.
